Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

Richard Derman1, Joseph D Kohles2, Ann Babbitt31Department of Obstetrics and Gynecology, Christiana Hospital, Newark, DE, USA; 2Roche, Nutley, NJ, USA; 3Greater Portland Bone and Joint Specialists, Portland, ME, USAAbstract: Data from two open-label trials (PRIOR and CURRENT) of women with postmenop...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard Derman, Joseph D Kohles, Ann Babbitt
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	osteoporosis bisphosphonate ibandronate gastrointestinal tolerability Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/0de30185bf0e4187965286a0d57c2d8c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0de30185bf0e4187965286a0d57c2d8c
record_format	dspace
spelling	oai:doaj.org-article:0de30185bf0e4187965286a0d57c2d8c2021-12-02T02:46:15ZGastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment1178-1998https://doaj.org/article/0de30185bf0e4187965286a0d57c2d8c2009-09-01T00:00:00Zhttps://www.dovepress.com/gastrointestinal-tolerability-with-ibandronate-after-previous-weekly-b-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Richard Derman1, Joseph D Kohles2, Ann Babbitt31Department of Obstetrics and Gynecology, Christiana Hospital, Newark, DE, USA; 2Roche, Nutley, NJ, USA; 3Greater Portland Bone and Joint Specialists, Portland, ME, USAAbstract: Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experienced GI irritation with bisphosphonate (BP) use. In PRIOR, women who had discontinued daily or weekly BP treatment due to GI intolerance received monthly oral or quarterly IV ibandronate for 12 months. The CURRENT subanalysis included women receiving weekly BP treatment who switched to monthly oral ibandronate for six months. GI symptom severity and frequency were assessed using the Osteoporosis Patient Satisfaction Questionnaire™. In PRIOR, mean GI tolerability scores increased significantly at month 1 from screening for both treatment groups (oral: 79.3 versus 54.1; IV: 84.4 versus 51.0; p < 0.001 for both). Most patients reported improvement in GI symptom severity and frequency from baseline at all post-screening assessments (>90% at Month 10). In the CURRENT subanalysis >60% of patients reported improvements in heartburn or acid reflux and >70% indicated improvement in other stomach upset at month 6. Postmenopausal women with GI irritability with daily or weekly BPs experienced improvement in symptoms with extended dosing monthly or quarterly ibandronate compared with baseline.Keywords: ibandronate, osteoporosis, bisphosphonate, gastrointestinalRichard DermanJoseph D KohlesAnn BabbittDove Medical PressarticleosteoporosisbisphosphonateibandronategastrointestinaltolerabilityGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 357-365 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteoporosis bisphosphonate ibandronate gastrointestinal tolerability Geriatrics RC952-954.6
spellingShingle	osteoporosis bisphosphonate ibandronate gastrointestinal tolerability Geriatrics RC952-954.6 Richard Derman Joseph D Kohles Ann Babbitt Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
description	Richard Derman1, Joseph D Kohles2, Ann Babbitt31Department of Obstetrics and Gynecology, Christiana Hospital, Newark, DE, USA; 2Roche, Nutley, NJ, USA; 3Greater Portland Bone and Joint Specialists, Portland, ME, USAAbstract: Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experienced GI irritation with bisphosphonate (BP) use. In PRIOR, women who had discontinued daily or weekly BP treatment due to GI intolerance received monthly oral or quarterly IV ibandronate for 12 months. The CURRENT subanalysis included women receiving weekly BP treatment who switched to monthly oral ibandronate for six months. GI symptom severity and frequency were assessed using the Osteoporosis Patient Satisfaction Questionnaire™. In PRIOR, mean GI tolerability scores increased significantly at month 1 from screening for both treatment groups (oral: 79.3 versus 54.1; IV: 84.4 versus 51.0; p < 0.001 for both). Most patients reported improvement in GI symptom severity and frequency from baseline at all post-screening assessments (>90% at Month 10). In the CURRENT subanalysis >60% of patients reported improvements in heartburn or acid reflux and >70% indicated improvement in other stomach upset at month 6. Postmenopausal women with GI irritability with daily or weekly BPs experienced improvement in symptoms with extended dosing monthly or quarterly ibandronate compared with baseline.Keywords: ibandronate, osteoporosis, bisphosphonate, gastrointestinal
format	article
author	Richard Derman Joseph D Kohles Ann Babbitt
author_facet	Richard Derman Joseph D Kohles Ann Babbitt
author_sort	Richard Derman
title	Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
title_short	Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
title_full	Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
title_fullStr	Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
title_full_unstemmed	Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
title_sort	gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/0de30185bf0e4187965286a0d57c2d8c
work_keys_str_mv	AT richardderman gastrointestinaltolerabilitywithibandronateafterpreviousweeklybisphosphonatetreatment AT josephdkohles gastrointestinaltolerabilitywithibandronateafterpreviousweeklybisphosphonatetreatment AT annbabbitt gastrointestinaltolerabilitywithibandronateafterpreviousweeklybisphosphonatetreatment
_version_	1718402143876022272

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

Ejemplares similares